Catiz
Tyrosine kinase inhibitor used for the treatment of patients with locally advanced or metastatic HER2-positive breast cancer, in combination with trastuzumab and capecitabine.
Therapeutic Area
Oncology
Active Ingredient
Tucatinib
Line
Oncology
Dosage forms
50 mg x 60 tablets
150 mg x 60 tablets
150 mg x 120 tablets
